Follow us on:
Breaking News
May 29, 2026
CP Direct: Friday Edition
Breaking News
FederalEquipment_ENL_052926_650x90

The Friday Brief for May 29, 2026: Partnerships Accelerating Innovative Treatments

 
The Friday Brief for May 29, 2026: Partnerships Accelerating Innovative Treatments

New collaborations aim at getting medicines to patients faster, while AI continues to impact efficiencies.
Watch Now >>

ContractPharma_Conference_2026_650x90
Top Headlines

Breaking News
Collaborations & Alliances

Pfizer, Innovent Strike $10.5 Billion Oncology Deal to Develop 12 Cancer Medicines

The partnership includes licensing, co-development, and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates.

SPONSOR

Boost Biosimilar Yields with Efficient-Pro Medium

See how Fresenius Kabi boosted titers, improved glycans, and reduced variants with Gibco Efficient-Pro Medium—ready for scale.

Breaking News

AI-Designed Drug Enters Phase I Trial

Quotient Sciences launches what it says is the first clinical study of an AI-developed drug formulation.

Breaking News

Samsung Bioepis Launches OPUVIZ Biosimilar in Europe

OPUVIZ becomes Samsung Bioepis’ fifth directly commercialized biosimilar product.

SPONSOR

[eBook] Equipment Sourcing & The Circular Advantage In Pharma Manufacturing

This eBook looks at how reuse and redeployment can help companies save time, manage capital more effectively, and reduce environmental impact—without compromising quality or compliance.

InformaPrinceton_Enl_051526_650x250

Breaking News
Trials & Filings

FDA Approves AbbVie’s DECNUPAZ for BPDCN

Approval gives adults with BPDCN a new treatment option for this rare, aggressive blood cancer.

Expert’s Opinion

3 Clinical Trial Rebound Trends – And How to Scale Smoothly

Phase II starts are increasing the fastest of all clinical phases, trials are running leaner, and the safety data challenge is growing.

SPONSOR

[VideoBite] Overcoming Solubility Challenges at Hovione’s Expanded NJ Site

David Basile of Hovione discusses expanded spray drying capacity in East Windsor and the benefits of integrated development, scale-up, and manufacturing at a single U.S. site.

Featured Resources

Solution Content Center SPOTLIGHT

AbbVie Contract Manufacturing

Vision. Expertise. Success. AbbVie Contract Manufacturing partners with companies across the globe to develop, scale and manufacture pharmaceutical products and bring them successfully to market. Drawing on more than four decades of success as the manufacturing division of AbbVie, we have the depth of experience and the technical knowledge to navigate issues and deliver the innovative solutions customers need. We are much more than a CMO – we are your partner for success. With foresight, scientific expertise and passion we anticipate the technical and compliance challenges along the entire pharmaceutical development journey through to commercialization. We see the complete picture to deliver our customer's vision. With full access to global state-of the-art facilities and world-class talent, our customers have come to depend on our service and quality to deliver real-world results.

 

Solution Center SPOTLIGHT

Lannett CDMO

Lannett CDMO is a US-based contract manufacturing organization with decades of pharmaceutical experience. We specialize in oral solid dose and non-injectable liquid manufacturing, high-potency compounds, and controlled substances. Our comprehensive services include advanced analytics, regulatory support, and supply chain management.